Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas

A phase II study of the Italian Sarcoma Group (ISG)

Salvatore Toma, Aniello Tucci, Giorgio Villani, Giacomo Carteni, Nicoletta Spadini, Raffaella Palumbo

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background: Doxorubicin remains one of the few drugs with consistent single agent activity in advanced Soft Tissue Sarcomas (STS) with a demonstrated dose-response relationship. Liposomal-encapsulated Doxorubicin (LED) has been shown to be at least as active as free doxorubicin in experimental models, and phase I and II human studies indicate that this novel strategy of drug delivery my have less myocardial toxicity. Few clinical trials in adult STS have been published until now, with disappointing and often contrasting results. Patients and Methods: Twenty-five consecutive patients with measurable advanced and/or metastatic STS, previously pretreated with anthracycline-based chemotherapy, were enrolled into the trial. LED (Caelyx) was administered over 1-hour intravenous infusion at the dose of 30 mg/m2 in the first 5 patients, then at the fixed dose of 50 mg/m2 in the subsequent 20 patients. Treatment was given on ambulatory basis, at 3-week intervals Antiemetics were generally not required and only used if indicated. Results: A total of 98 courses of chemotherapy were given (median 4 per patient, range 2 to 5). Amongst the 25 evaluable patients, there were 3 partial responses (12%, 95% confidence interval 4.2% to 29.9%) lasting 3-9+ months and all occurring in patients treated at 50 mg/m2/cycle. In addition, 2 minor responses (4+ months) and 17 stable disease (2-7+ months) were observed; the remaining 3 patients progressed while on therapy. The median delivered drug dose-intensity was 13.3 mg/m2/week (range 10 to 16.6 mg/m2/week). Treatment was well tolerated, with no patient requiring dose reduction or therapy delay because of toxicity. Only 2 cases of WHO grade 3 toxicity occurred consisting of neutropenia and scrotal skin toxicity; respectively; no cardiotoxicity was seen. Conclusions: This study shows that Caelyx has some activity in advanced, anthracycline-pretreated STS, with favourable toxic profile. From the analysis of available experiences it emerges that liposomal doxorubicin has not been tested at doses adequate to exploit the antitumor effects of the drug, being the reached dose-intensity being even lower than those deemed critical for obtaining optimal responses to free doxorubicin. We suggest that further and better addressed studies be performed in STS, including patients with less advanced stages of disease, focused on attempting to delivery the drug at optimal doses.

Original languageEnglish
Pages (from-to)485-491
Number of pages7
JournalAnticancer Research
Volume20
Issue number1 B
Publication statusPublished - 2000

Fingerprint

Sarcoma
Doxorubicin
Anthracyclines
Pharmaceutical Preparations
liposomal doxorubicin
Drug Therapy
Antiemetics
Poisons
Therapeutics
Neutropenia
Intravenous Infusions
Antineoplastic Agents
Theoretical Models
Clinical Trials
Confidence Intervals
Skin

Keywords

  • Chemotherapy
  • Dose-intensity
  • Liposomal doxorubicin
  • Soft tissue sarcomas

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas : A phase II study of the Italian Sarcoma Group (ISG). / Toma, Salvatore; Tucci, Aniello; Villani, Giorgio; Carteni, Giacomo; Spadini, Nicoletta; Palumbo, Raffaella.

In: Anticancer Research, Vol. 20, No. 1 B, 2000, p. 485-491.

Research output: Contribution to journalArticle

Toma, Salvatore ; Tucci, Aniello ; Villani, Giorgio ; Carteni, Giacomo ; Spadini, Nicoletta ; Palumbo, Raffaella. / Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas : A phase II study of the Italian Sarcoma Group (ISG). In: Anticancer Research. 2000 ; Vol. 20, No. 1 B. pp. 485-491.
@article{e5a449528d0d4b5b8bab50a304606b42,
title = "Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: A phase II study of the Italian Sarcoma Group (ISG)",
abstract = "Background: Doxorubicin remains one of the few drugs with consistent single agent activity in advanced Soft Tissue Sarcomas (STS) with a demonstrated dose-response relationship. Liposomal-encapsulated Doxorubicin (LED) has been shown to be at least as active as free doxorubicin in experimental models, and phase I and II human studies indicate that this novel strategy of drug delivery my have less myocardial toxicity. Few clinical trials in adult STS have been published until now, with disappointing and often contrasting results. Patients and Methods: Twenty-five consecutive patients with measurable advanced and/or metastatic STS, previously pretreated with anthracycline-based chemotherapy, were enrolled into the trial. LED (Caelyx) was administered over 1-hour intravenous infusion at the dose of 30 mg/m2 in the first 5 patients, then at the fixed dose of 50 mg/m2 in the subsequent 20 patients. Treatment was given on ambulatory basis, at 3-week intervals Antiemetics were generally not required and only used if indicated. Results: A total of 98 courses of chemotherapy were given (median 4 per patient, range 2 to 5). Amongst the 25 evaluable patients, there were 3 partial responses (12{\%}, 95{\%} confidence interval 4.2{\%} to 29.9{\%}) lasting 3-9+ months and all occurring in patients treated at 50 mg/m2/cycle. In addition, 2 minor responses (4+ months) and 17 stable disease (2-7+ months) were observed; the remaining 3 patients progressed while on therapy. The median delivered drug dose-intensity was 13.3 mg/m2/week (range 10 to 16.6 mg/m2/week). Treatment was well tolerated, with no patient requiring dose reduction or therapy delay because of toxicity. Only 2 cases of WHO grade 3 toxicity occurred consisting of neutropenia and scrotal skin toxicity; respectively; no cardiotoxicity was seen. Conclusions: This study shows that Caelyx has some activity in advanced, anthracycline-pretreated STS, with favourable toxic profile. From the analysis of available experiences it emerges that liposomal doxorubicin has not been tested at doses adequate to exploit the antitumor effects of the drug, being the reached dose-intensity being even lower than those deemed critical for obtaining optimal responses to free doxorubicin. We suggest that further and better addressed studies be performed in STS, including patients with less advanced stages of disease, focused on attempting to delivery the drug at optimal doses.",
keywords = "Chemotherapy, Dose-intensity, Liposomal doxorubicin, Soft tissue sarcomas",
author = "Salvatore Toma and Aniello Tucci and Giorgio Villani and Giacomo Carteni and Nicoletta Spadini and Raffaella Palumbo",
year = "2000",
language = "English",
volume = "20",
pages = "485--491",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 B",

}

TY - JOUR

T1 - Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas

T2 - A phase II study of the Italian Sarcoma Group (ISG)

AU - Toma, Salvatore

AU - Tucci, Aniello

AU - Villani, Giorgio

AU - Carteni, Giacomo

AU - Spadini, Nicoletta

AU - Palumbo, Raffaella

PY - 2000

Y1 - 2000

N2 - Background: Doxorubicin remains one of the few drugs with consistent single agent activity in advanced Soft Tissue Sarcomas (STS) with a demonstrated dose-response relationship. Liposomal-encapsulated Doxorubicin (LED) has been shown to be at least as active as free doxorubicin in experimental models, and phase I and II human studies indicate that this novel strategy of drug delivery my have less myocardial toxicity. Few clinical trials in adult STS have been published until now, with disappointing and often contrasting results. Patients and Methods: Twenty-five consecutive patients with measurable advanced and/or metastatic STS, previously pretreated with anthracycline-based chemotherapy, were enrolled into the trial. LED (Caelyx) was administered over 1-hour intravenous infusion at the dose of 30 mg/m2 in the first 5 patients, then at the fixed dose of 50 mg/m2 in the subsequent 20 patients. Treatment was given on ambulatory basis, at 3-week intervals Antiemetics were generally not required and only used if indicated. Results: A total of 98 courses of chemotherapy were given (median 4 per patient, range 2 to 5). Amongst the 25 evaluable patients, there were 3 partial responses (12%, 95% confidence interval 4.2% to 29.9%) lasting 3-9+ months and all occurring in patients treated at 50 mg/m2/cycle. In addition, 2 minor responses (4+ months) and 17 stable disease (2-7+ months) were observed; the remaining 3 patients progressed while on therapy. The median delivered drug dose-intensity was 13.3 mg/m2/week (range 10 to 16.6 mg/m2/week). Treatment was well tolerated, with no patient requiring dose reduction or therapy delay because of toxicity. Only 2 cases of WHO grade 3 toxicity occurred consisting of neutropenia and scrotal skin toxicity; respectively; no cardiotoxicity was seen. Conclusions: This study shows that Caelyx has some activity in advanced, anthracycline-pretreated STS, with favourable toxic profile. From the analysis of available experiences it emerges that liposomal doxorubicin has not been tested at doses adequate to exploit the antitumor effects of the drug, being the reached dose-intensity being even lower than those deemed critical for obtaining optimal responses to free doxorubicin. We suggest that further and better addressed studies be performed in STS, including patients with less advanced stages of disease, focused on attempting to delivery the drug at optimal doses.

AB - Background: Doxorubicin remains one of the few drugs with consistent single agent activity in advanced Soft Tissue Sarcomas (STS) with a demonstrated dose-response relationship. Liposomal-encapsulated Doxorubicin (LED) has been shown to be at least as active as free doxorubicin in experimental models, and phase I and II human studies indicate that this novel strategy of drug delivery my have less myocardial toxicity. Few clinical trials in adult STS have been published until now, with disappointing and often contrasting results. Patients and Methods: Twenty-five consecutive patients with measurable advanced and/or metastatic STS, previously pretreated with anthracycline-based chemotherapy, were enrolled into the trial. LED (Caelyx) was administered over 1-hour intravenous infusion at the dose of 30 mg/m2 in the first 5 patients, then at the fixed dose of 50 mg/m2 in the subsequent 20 patients. Treatment was given on ambulatory basis, at 3-week intervals Antiemetics were generally not required and only used if indicated. Results: A total of 98 courses of chemotherapy were given (median 4 per patient, range 2 to 5). Amongst the 25 evaluable patients, there were 3 partial responses (12%, 95% confidence interval 4.2% to 29.9%) lasting 3-9+ months and all occurring in patients treated at 50 mg/m2/cycle. In addition, 2 minor responses (4+ months) and 17 stable disease (2-7+ months) were observed; the remaining 3 patients progressed while on therapy. The median delivered drug dose-intensity was 13.3 mg/m2/week (range 10 to 16.6 mg/m2/week). Treatment was well tolerated, with no patient requiring dose reduction or therapy delay because of toxicity. Only 2 cases of WHO grade 3 toxicity occurred consisting of neutropenia and scrotal skin toxicity; respectively; no cardiotoxicity was seen. Conclusions: This study shows that Caelyx has some activity in advanced, anthracycline-pretreated STS, with favourable toxic profile. From the analysis of available experiences it emerges that liposomal doxorubicin has not been tested at doses adequate to exploit the antitumor effects of the drug, being the reached dose-intensity being even lower than those deemed critical for obtaining optimal responses to free doxorubicin. We suggest that further and better addressed studies be performed in STS, including patients with less advanced stages of disease, focused on attempting to delivery the drug at optimal doses.

KW - Chemotherapy

KW - Dose-intensity

KW - Liposomal doxorubicin

KW - Soft tissue sarcomas

UR - http://www.scopus.com/inward/record.url?scp=0034109686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034109686&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 485

EP - 491

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 B

ER -